Grifols

Biotest is a specialized company focused on innovative haematology, clinical immunology, and intensive care medicine. It develops, manufactures, and markets plasma proteins and biotherapeutic drugs, with a value chain that encompasses pre-clinical and clinical development to global marketing and distribution. The company produces immunoglobulins, clotting factors, and albumins derived from human blood plasma, processed in advanced fractionation facilities in Europe. Additionally, Biotest develops monoclonal antibodies targeting conditions such as plasma cell cancer and systemic lupus erythematosus through recombinant technologies. The majority of its revenue is generated from its Therapy segment, with significant operations in Central Europe and other regions. Biotest employs over 2,500 people worldwide and focuses on creating effective medications for life-threatening diseases, including blood coagulation disorders, severe infections, and immune system disorders.

Prometic Plasma Resources is a healthcare center that specializes in blood donation services.

GigaGen, Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing innovative antibody therapies aimed at treating cancer and immune deficiencies. Founded in 2010, the company leverages advanced technologies, including microfluidics, bioinformatics, sequencing, and genetic engineering, to explore B and T cell repertoires for full-length natively paired antibodies and T cell receptors. GigaGen is advancing a diverse pipeline of biotherapeutics, which includes novel oncology antibody drug combinations and the first recombinant polyclonal hyperimmune gammaglobulin. The company’s proprietary antibody discovery technology enables rapid characterization of immune system cells, facilitating the selection of drug targets and identification of viable drug candidates for preclinical efficacy assessments.

Alkahest, Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, founded in 2014. The company specializes in developing therapies derived from blood to address neurological diseases, particularly those associated with aging, such as Alzheimer’s disease and Parkinson’s disease. Alkahest's innovative research has shown that factors in the blood plasma of younger organisms can reverse cognitive deficits associated with aging and neurodegenerative diseases in animal models. The company aims to enhance health and vitality by creating transformative treatments that mitigate the negative effects of aging. Alkahest operates as a subsidiary of Grifols, a global healthcare company known for its plasma therapies.

MedKeeper is a provider of mobile and web-based software applications tailored for hospital pharmacies, focusing on enhancing efficiency and compliance in pharmacy operations. The company's secure, hosted solutions are utilized by numerous hospitals and medical centers to facilitate communication, streamline workflows, and improve overall productivity. MedKeeper's applications offer real-time reporting and analytics, medication tracking, inspections, and quality assurance features, enabling healthcare institutions to leverage technology for better operational outcomes. By delivering flexible and economical tools, MedKeeper supports pharmacies in promoting regulatory compliance and optimizing their services.

GigaGen, Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing innovative antibody therapies aimed at treating cancer and immune deficiencies. Founded in 2010, the company leverages advanced technologies, including microfluidics, bioinformatics, sequencing, and genetic engineering, to explore B and T cell repertoires for full-length natively paired antibodies and T cell receptors. GigaGen is advancing a diverse pipeline of biotherapeutics, which includes novel oncology antibody drug combinations and the first recombinant polyclonal hyperimmune gammaglobulin. The company’s proprietary antibody discovery technology enables rapid characterization of immune system cells, facilitating the selection of drug targets and identification of viable drug candidates for preclinical efficacy assessments.

Hologic - NAT donor screening unit engages in research, development and manufacture of assays and instruments based on NAT (Nucleic Acid Testing) technology for transfusion and transplantation screening

Singulex, Inc. is an immunodiagnostics company specializing in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company develops the Sgx Clarity System, an advanced in vitro diagnostics platform that detects low abundance biomarkers with high sensitivity, down to femtograms per milliliter. This system supports cardiovascular health management through services aimed at clinicians and personalized wellness programs for patients. Singulex offers ultra-sensitive immunoassay solutions and laboratory testing services that enhance patient care by facilitating proactive health management and aiding in the discovery of new therapeutics. The company serves a diverse clientele including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Singulex, originally established as BioProfile Corporation in 1997, rebranded in 2003 and is headquartered in Alameda, California, with an additional office in Basel, Switzerland.

Alkahest, Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, founded in 2014. The company specializes in developing therapies derived from blood to address neurological diseases, particularly those associated with aging, such as Alzheimer’s disease and Parkinson’s disease. Alkahest's innovative research has shown that factors in the blood plasma of younger organisms can reverse cognitive deficits associated with aging and neurodegenerative diseases in animal models. The company aims to enhance health and vitality by creating transformative treatments that mitigate the negative effects of aging. Alkahest operates as a subsidiary of Grifols, a global healthcare company known for its plasma therapies.

Kiro Robotics is a technology company that specializes in the automation of machinery for the hospital sector. It concentrates on developing machines and equipment to automate and control key points of hospital processes, and hospital pharmacy processes in particular, improving the safety of patients and health professionals alike, and delivering increased efficiency.

Celyad Oncology is a clinical-stage biopharmaceutical company based in Mont-Saint-Guibert, Belgium, specializing in the development of CAR-T cell therapies for cancer treatment. The company’s primary product candidates include CYAD-01 and CYAD-02, both autologous cell therapies currently undergoing Phase I clinical trials for relapsed/refractory acute myeloid leukemia. Celyad is also advancing CYAD-101, an allogeneic cell therapy in Phase I trials for metastatic colorectal cancer, and CYAD-103, which is in preclinical development for solid tumors. Other preclinical candidates include CYAD-211 for multiple myeloma, CYAD-221 for B-cell malignancies, and CYAD-231, a dual-specific CAR-T targeting NKG2D and an undisclosed membrane protein. Celyad has established licensing agreements with Novartis regarding allogeneic CAR-T cells and collaborations with Horizon Discovery Group for technology development. The company was founded in 2004 and has previously operated under the name Cardio3 BioSciences.

Progenika Biopharma is a biotechnology company located in Derio, Spain, specializing in the development, production, and commercialization of molecular biology tests. The company focuses on blood group genotyping, diagnosing complex genetic diseases, and monitoring health conditions. Progenika Biopharma designs in vitro diagnostic tests that address a wide array of clinical needs, including tools for disease diagnosis and prognosis, as well as predicting patient responses to drug treatments. Through its innovative solutions, Progenika Biopharma aims to enhance healthcare outcomes by providing precise and reliable diagnostic information.

VCN Biosciences is a biotechnology company focused on developing innovative therapies for tumors that currently lack effective treatment options. Utilizing a proprietary oncolytic adenovirus technology platform, the company designs agents that selectively replicate and amplify within tumor cells. This targeted approach aims to enhance treatment efficacy for challenging conditions, such as pancreatic adenocarcinomas and other refractory tumors. Through its research and development efforts, VCN Biosciences seeks to advance the field of oncology and improve patient outcomes in the fight against cancer.

Araclon Biotech is a biotechnology company focused on the research and development of therapies and diagnostic methods for degenerative diseases, particularly Alzheimer's disease. The company specializes in developing tests for analyzing β-amyloid peptides in human plasma, which are crucial for diagnosing Alzheimer's. In addition to diagnostics, Araclon Biotech is engaged in the creation of immunotherapy vaccines aimed at targeting these β-amyloid peptides, thereby enabling healthcare professionals to prevent the disease or delay its symptoms. The company also involves itself in the scientific investigation, commercialization, and exploitation of pharmacological and biotechnological products, as well as the management of patents related to its innovations.

Talecris Biotherapeutics is a biopharmaceutical company specializing in the production and marketing of plasma-derived protein therapies. Established in 2004 and headquartered in Barcelona, Spain, the company develops and distributes a range of therapies aimed at treating individuals with chronic and acute immune deficiency disorders, alpha-1 antitrypsin deficiency, infectious diseases, hemophilia, and severe burns. Its product portfolio includes Hyperimmunes, which are antibody preparations for various conditions such as hepatitis, rabies, and tetanus, as well as treatments for Rh negative women pregnant with Rh positive children. Additionally, Talecris offers albumin under brand names like Plasbumin and Plasmanate, along with plasma-derived hemostasis products designed for individuals lacking essential blood factors. Through its diverse offerings, Talecris Biotherapeutics plays a crucial role in addressing complex health challenges associated with blood and immune system disorders.

Celyad Oncology is a clinical-stage biopharmaceutical company based in Mont-Saint-Guibert, Belgium, specializing in the development of CAR-T cell therapies for cancer treatment. The company’s primary product candidates include CYAD-01 and CYAD-02, both autologous cell therapies currently undergoing Phase I clinical trials for relapsed/refractory acute myeloid leukemia. Celyad is also advancing CYAD-101, an allogeneic cell therapy in Phase I trials for metastatic colorectal cancer, and CYAD-103, which is in preclinical development for solid tumors. Other preclinical candidates include CYAD-211 for multiple myeloma, CYAD-221 for B-cell malignancies, and CYAD-231, a dual-specific CAR-T targeting NKG2D and an undisclosed membrane protein. Celyad has established licensing agreements with Novartis regarding allogeneic CAR-T cells and collaborations with Horizon Discovery Group for technology development. The company was founded in 2004 and has previously operated under the name Cardio3 BioSciences.